TY  - GEN
AU  - Rajeshkumar,N V
AU  - De Oliveira,Elizabeth
AU  - Ottenhof,Niki
AU  - Watters,James
AU  - Brooks,David
AU  - Demuth,Tim
AU  - Shumway,Stuart D
AU  - Mizuarai,Shinji
AU  - Hirai,Hiroshi
AU  - Maitra,Anirban
AU  - Hidalgo,Manuel
TI  - MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts
SN  - 1557-3265
PY  - 2011///0915
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carcinoma, Pancreatic Ductal
KW  - drug therapy
KW  - Cell Cycle Proteins
KW  - antagonists & inhibitors
KW  - Cell Line, Tumor
KW  - Deoxycytidine
KW  - administration & dosage
KW  - Disease Progression
KW  - Drug Synergism
KW  - Female
KW  - Genes, p53
KW  - Humans
KW  - Mice
KW  - Mice, Nude
KW  - Mutation
KW  - physiology
KW  - Neoplasms
KW  - Nuclear Proteins
KW  - Pancreatic Neoplasms
KW  - Protein Kinase Inhibitors
KW  - Protein-Tyrosine Kinases
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Pyrimidinones
KW  - Tumor Burden
KW  - drug effects
KW  - Xenograft Model Antitumor Assays
KW  - Gemcitabine
N1  - Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-10-2580
ER  -